This site is intended for healthcare professionals

FDA advisory committee votes on recommending CCX 168 for approval in vasculitis.- ChemoCentryx

Read time: 1 mins
Last updated:8th May 2021
Published:8th May 2021
ChemoCentryx announced the outcome of the FDA Arthritis Advisory Committee on CCX 168 (avacopan) for the treatment of Antineutrophil Cytoplasmic Autoantibody (ANCA)-associated vasculitis (or AAV).
Condition: Vasculitis
Type: drug
Register for free access to this exclusive healthcare learning resource

Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest